Skip to content
Subscriber Only

Endo to Pay $193 Million in Lidoderm Marketing Probe

Endo Health Solutions Inc. will pay $193 million to resolve government probes and whistle-blower lawsuits focusing on allegations that the drugmaker marketed its Lidoderm shingles drug for unapproved uses.

Endo will pay $20.8 million in criminal penalties and forfeitures and $171.9 million in civil false-claims settlements with the states and the U.S. government as part of the accord, the U.S. Justice Department said today in a statement. The drugmaker also entered a deferred-prosecution agreement.